Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. There can be no assurance that that the data presented during the 2010 International Scientific Conference of the World Allergy Association (WAO) regarding Cinryze is predictive of how Cinryze will perform in commercial usage.  Cinryze is currently available only in the United States.  Cinryze is not approved in the U.S. for acute treatment of attacks nor has the safety and effectiveness of Cinryze been established in pediatric patients with HAE. We cannot assure that current or future studies with Cinryze in the patient populations described in the WAO presentations may demonstrate the safety and efficacy profile of Cinryze. The EMA may view the data regarding the use of Cinryze for acute treatment and / or prevention of HAE we have submitted in the MAA as insufficient or inconclusive, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment and / or prevention of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the European market.  For example, in June 2009, the U.S. FDA issued a complete response letter and requested an additional clinical study, due to their opinion that the placebo controlled study submitted in support of the sBLA for acute treatment of HAE lacked robustness. These factors, and other factors, including, but not limited
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011  Thoratec (NASDAQ: THOR), a world leader in device-based ... failing hearts, said today it will be participating in ... Tuesday, December 13. Taylor C. Harris, Senior ... an update on the company, beginning at 10:15 a.m., ...
...  VolitionRX Limited (VNRX.OB), a life sciences company focused on ... it will issue US$1,110,000 worth of shares of its ... issuance is the final requirement of the Share Purchase ... June 2011) between ValiRx and Singapore Volition Pte Limited, ...
Cached Medicine Technology:VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement 2
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... WA April 18, 2014) Benaroya Research Institute ... research how blocking a particular molecule in metastatic breast ... the number of lung metastases. BRI scientists have found ... can shrink tumors by 60 - 80 percent and ... the lung. The $1.8 million five-year grant comes from ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... Oct. 15 One Heartland will host "S,more to Love", a ... Open House Lofts, NYC to benefit Birch Family Camp. , Celebrating ... (over 200 family members) from the 5 boroughs of NYC, along ... building at a camp facility located in the Hudson Valley. ...
... 15 The Longaberger Company is teaming up with the ... against breast cancer. As part of the "Crucial Catch" campaign ... players - in partnership with the American Cancer Society - ... feature players, coaches and referees wearing pink game apparel to ...
... TALLAHASSEE, Fla. -- A Florida State University College of Medicine ... Institutes of Health (NIH) totaling $2.4 million to continue her ... months. Amy Wetherby is director of the Autism Institute ... WORDS Project has screened children to identify early red flags ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... Oct. 15 Astrup Drug Inc. has announced ... (ECRS) point-of-sale retail automation suite in their 11 ... selected by Astrup Drug to seamlessly automate their ... convenience/fuel integration, warehousing, front-end inventory control, and centralized ...
... for Presentation Also Nominated for Prestigious Prize , ... nine abstracts based on research by a total of 15 ... doctors, researchers and psychological social workers will be featured this ... meeting in Atlanta. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090203/DC66439LOGO ...
Cached Medicine News:Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 3Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Astrup Drug Implements ECRS Retail Solution Suite to Address Diverse Business Requirements 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 3Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 4
Softsplint after bunion surgery. Hook-and-loop closure. Maintains hallux positioning and metatarsophalangeal alignment. Washable....
... The Pediatric Ankle Cryo/Cuff is specifically designed ... 7). Using a combination of controlled compression ... and pain. The Pediatric Ankle Cryo/Cuff is ... hemorrhagic episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff ...
... Air-Stirrup Plus combines the clinically proven ... wrap. In addition, a comprehensive instruction ... Plus and provides information on treatment ... ankle sprain management.,Each Air-Stirrup Ankle Brace ...
... Full Transportability: Innovative design allows ... plug in for therapy or when ... Controller: Choose the prophylactic method to ... or both simultaneously. ,Automatic Garment Detection: ...
Medicine Products: